OOIR: Observatory of International Research

Papers

(The H4-Index of Cancer is 43. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Cutaneous β‐HPV may predict cutaneous squamous cell carcinoma	449
The role of relative advantage for development of sequencing‐based diagnostics for pediatric cancer in low‐ and middle‐income countries	301
	214
Active surveillance after neoadjuvant chemoradiotherapy for esophageal cancer	192
Issue Information	191
The economics of advanced and unresectable hepatocellular carcinoma	138
New standard of care for multiple myeloma?	132
Updated American Cancer Society lung cancer screening guidelines	106
Best of both worlds? Linking comprehensive and noncomprehensive cancer centers	74
Targeting HER2 in lung cancers: Evolving treatment landscape and drug development strategies	73
Smoking cessation services and shared decision‐making practices among lung cancer screening facilities: A cross‐sectional study	62
MRI is more accurate than a PSMA PET/CT scan for prostate cancer diagnosis	62
Serum of interleukin‐6 and procalcitonin as early diagnostic markers for the identification of poor hematopoietic reconstitution following allogeneic hematopoietic stem cell transplantation	60
Potential of circulating tumor DNA to refine immunotherapy	60
Erratum to “Landscape of DNA damage response gene alterations in breast cancer: A comprehensive investigation”	59
Reply to “Enhancing the role of social work in managing cancer risks among LGBTQ+ populations” and “The urgency of systematically acquiring sexual orientation and gender identity data to ensure equity	59
Aspirin but not statins is inversely related to gastric cancer with a duration–risk effect: Results from the Stomach Cancer Pooling Project Consortium	57
Multicenter study of pediatric Epstein‐Barr virus–negative monomorphic post solid organ transplant lymphoproliferative disorders	57
Patterns of failure in pediatric medulloblastoma and implications for hippocampal sparing	57
Family characteristics and childcare patterns associated with early social functioning in cancer‐bereaved parents	56
	55
Accelerated approval of multiple myeloma therapies	54
Issue Information	53
Erratum to “Incorporation of alemtuzumab into frontline therapy of adult acute lymphoblastic leukemia: Results of Cancer and Leukemia Group B 10102 (Alliance), a phase 1/2 study”	53
“Cancer Statistics, 2025” provides data on cancer occurrence and outcomes	52

Top advances of the year: Neoadjuvant immunotherapy in melanoma	52
Reply to “Empathic communication: The premise of inclusive care for historically excluded populations”	51
Erratum to “Chimeric antigen receptor–based immunotherapy in breast cancer: Recent progress in China”	51
	50
What enhanced recovery means for patients with cancer undergoing surgery	50
	50
Detection of recurrent colorectal cancer with high specificity using a reporting threshold for circulating tumor DNA methylated in BCAT1 and IKZF1	50
Issue Information	49
Issue Information	48
Association of the social disorganization index with time to first septic shock event in children with acute myeloid leukemia	48
Erratum to “Unhealthy lifestyle behaviors, overweight, and obesity among childhood cancer survivors in the Netherlands: A DCCSS LATER study”	47
	47
Implantable cardioverter defibrillators in people dying with cancer: A SEER‐Medicare analysis of ICD prevalence and association with aggressive end‐of‐life care	45
New test for detecting cervical adenocarcinoma	45
Stopping immunotherapy after 2 years is practical in patients with advanced non–small cell lung cancer	43
Can we avoid thoracic radiotherapy in young females with Hodgkin lymphoma?	43
The Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer (CISTO) study: Lessons learned about management and patient enrollment in a large, pragmatic, patient‐centere	43
Understanding risk factors for cancer: What's new and how can it help reduce the cancer burden?	43